Safety and Tolerability of Aripiprazole in Adolescents With Schizophrenia or Children and Adolescents With Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features.

Inclusion Criteria:

- Subjects 13-17 years old (Schizophrenia); Subjects 10-17 years old (Bipolar manic or
mixed episode)* [*Bulgaria will enroll Schizophrenia subjects only.]

- Subjects with a current diagnosis of schizophrenia, and a history of the illness
(diagnosis or symptoms) for at least 6 months prior to screening (as per subject,
family, or healthcare provider, or by previous medical records).

- Subjects with a current diagnosis of bipolar I disorder, manic or mixed episode with
or without psychotic features (diagnosis or symptoms) experiencing symptoms for at
least 1 week prior to screening. * [*These subjects will not be eligible to enroll in
Bulgaria]

- Subjects who have shown previous response to antipsychotic treatment (other than
clozapine) and are not resistant to treatment with other antipsychotics.

- Subjects who are currently being treated with oral antipsychotics other than
clozapine, and are not resistant to treatment with other antipsychotics.

- Inpatient or outpatient status, with the exception of acute hospitalization due to
psychiatric reasons at the time of screening or before Phase 2.

Exclusion Criteria:

- All subjects: diagnosis of schizoaffective disorder, autism, pervasive developmental
disorder (PDD), OCD, or PTSD.

- Subjects with schizophrenia: a current major depressive episode.

- Subjects with bipolar manic or mixed episode: presenting with a clinical picture
and/or history that is consistent with a diagnosis of bipolar II disorder or bipolar
disorder not otherwise specified.

- Subjects with delirium, dementia, amnesia or other cognitive disorders; subjects with
psychotic symptoms that are better accounted for by another general medical
condition(s) or direct effect of a substance (i.e., medication, illicit drug use,
etc.).

- Subjects with any neurological disorder, with the exception of Tourette's syndrome.

- Subjects experiencing major depressive episode at the time of screening other than
subjects diagnosed with bipolar I disorder mixed episode.

- Subjects who are currently receiving clozapine or have received clozapine at any time
in the past are ineligible for entry into the study.

- Subjects who meet the DSM-IV-TR criteria for substance dependence (including alcohol
and benzodiazepines, but excluding caffeine and nicotine) within the past 180 days
prior to screening.

- Subjects who have epilepsy, a history of seizures (except for a single childhood
febrile seizure or post-traumatic seizure), or a history of severe head trauma or
stroke, or have a history or current evidence of other unstable medical conditions.

- Subjects with a history of subclinical hypothyroidism (TSH ≥ 4.0 mIU/L), known
hypothyroidism, or hyperthyroidism (unless the condition has been stabilized with
medications for at least 90 days prior to entry into Phase 1 or Phase 2).

- Subjects who have a medical history of uncontrolled diabetes, labile or unstable
diabetes (brittle diabetes), newly diagnosed diabetes, or clinically significant
abnormal blood glucose levels (defined as fasting blood glucose ≥ 125 mg/dL).